SCHEMBL31378780

SCHEMBL31378780

Nc1cc2ccc(Cl)cc2[nH]c1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 3/20 0.64
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55
GRIN2B Q13224 1/20 0.55
GRIN2C Q14957 1/20 0.55
GRIN3A Q8TCU5 1/20 0.55
F11 P03951 1/20 0.50
PARP1 P09874 1/20 0.49
ALOX15 P16050 4/20 0.45
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
BACE1 P56817 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
IDH1 O75874 1/20 0.44
TYMS P04818 2/20 0.43
ROCK2 O75116 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31378871 0.85 DAO (0.64) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8925766 0.79 DAO (0.53) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7811758 0.79 LMNA (0.60) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL7346243 0.78 TYMS (0.50) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL2463866 0.78 DAO (0.64) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL4388117 0.78 DAO (0.64) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL31378775 0.78 DAO (0.64) DAOPARP1TYMSFLT3AKR1B1
SCHEMBL16767847 0.78 DAO (1.00) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL8872186 0.77 DAO (0.62) DAOGRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL28239799 0.76 AOC3 (0.54) DAOGRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-29 US disclosed
WO-2025030163-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171431-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TRHR, TSHR DAO 495/4885GRIN2D 3840/4885GRIN3B 2634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.